CoChat
Sign Up
Cited by 135Cholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Clinical Pharmacokinetics of Galantamine

Farlow, Martin R·2003·Clinical Pharmacokinetics
DOI 10.2165/00003088-200342150-00005
Open this paper in CoChat — free account

Abstract

Galantamine is the most recently approved cholinergic drug for the treatment of Alzheimer's disease, the most common type of dementia. Vascular dementia and Alzheimer's disease with cerebrovascular disease are also common in older patients. Dementia affects cognition, causes losses in ability to perform activities of daily living and often results in the emergence of psychiatric and abnormal behavioural symptoms. Dementia also results in an ever-increasing burden and a decreased quality of life for caregivers. Treatments for dementia, particularly Alzheimer's disease, have focused on improving function in the cholinergic system. Vascular dementia and diffuse Lewy body dementia are also associated with significant defects in cholinergic function. Galantamine works by inhibiting acetylcholinesterase and by allosterically modulating nicotinic receptors. In clinical trials, galantamine has shown benefits in the domains of cognition, function in activities of daily living, and behaviour. Galantamine is about 90% bioavailable and displays linear pharmacokinetics. It has a relatively large volume of distribution and low protein binding. Metabolism is primarily through the cytochrome P450 system, specifically the CYP2D6 and CYP3A4 isoenzymes. Population pharmacokinetic modelling with galantamine has shown that the variables affecting clearance are age, sex, and bodyweight. Model simulations demonstrate the importance of a slower dose-escalation schedule in patients with moderate hepatic impairment. In several large trials, galantamine has been shown to be well tolerated, with most adverse events being mild-to-moderate and gastrointestinal in nature. Based on the literature and clinical trial experience, galantamine appears to be an excellent treatment option for patients with Alzheimer's disease, vascular dementia or Alzheimer's disease with cerebrovascular disease.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003088-200342150-00005

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 58 references

Research works printed but not linked: 9

  1. Pendlebury, 1996, Clin Symp, 48, 2
  2. Tanaka, 1993, Arch Int Pharmacodyn Ther, 323, 85
  3. De Angelis, 1972, Anesth Analg, 51, 196
  4. Cozanitis, 1971, Anaesthesist, 20, 226
  5. Bores, 1996, J Pharmacol Exp Ther, 277, 728
  6. Thomsen, 1991, Eur J Clin Chem Clin Biochem, 29, 487
  7. Pereira, 1994, J Pharmacol Exp Ther, 270, 768
  8. Schrattenholz, 1996, Mol Pharmacol, 49, 1
  9. Pereira, 1993, J Pharmacol Exp Ther, 265, 1474

Cited by

Sorted by citations

Items 101–135 of 135

Related

See all

Metadata

Authors
Farlow, M. R.
Affiliations
Indiana University Indianapolis (US)
Corresponding author
Farlow, Martin R
ORCID
Farlow, Martin R
Venue
Clinical Pharmacokinetics
Publisher
Springer Science and Business Media LLC
Published
2003
Volume
42
Issue
15
Pages
1383-1392
ISSN
0312-5963 (ISSN-L)
DOI
10.2165/00003088-200342150-00005
OpenAlex
W1983913269
Cited by
134
References
58
Citations by year
2026: 4 · 2025: 9 · 2024: 15 · 2023: 5 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 7 · 2018: 7 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 5 · 2012: 6
FWCI
0.38
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
galantamine, pharmacokinetics, Alzheimer's disease, vascular dementia, acetylcholinesterase inhibition, CYP2D6, CYP3A4, liver dysfunction, dose escalation, population pharmacokinetic model, drug metabolism, adverse events, dementia treatment
MeSH terms
Adult, Aged, Alzheimer Disease, Biological Availability, Cholinesterase Inhibitors, Clinical Trials as Topic, Drug Interactions, Female, Galantamine, Half-Life, Humans, Male, Middle Aged, Area Under Curve

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review